Neuroprotection: models, mechanisms and therapies
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
Weinheim
Wiley-VCH
2004
|
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | XX, 369 S. Ill., graph. Darst. |
| ISBN: | 3527308164 |
Staff View
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV017687679 | ||
| 003 | DE-604 | ||
| 005 | 20191015 | ||
| 007 | t | ||
| 008 | 031125s2004 gw ad|| |||| 00||| eng d | ||
| 016 | 7 | |a 969303823 |2 DE-101 | |
| 020 | |a 3527308164 |9 3-527-30816-4 | ||
| 035 | |a (OCoLC)56538914 | ||
| 035 | |a (DE-599)BVBBV017687679 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c DE | ||
| 049 | |a DE-355 | ||
| 050 | 0 | |a RC358 | |
| 082 | 0 | |a 616.806 |2 22 | |
| 084 | |a YG 1600 |0 (DE-625)153474:12905 |2 rvk | ||
| 084 | |a YG 4015 |0 (DE-625)153494:12921 |2 rvk | ||
| 084 | |a CZ 1380 |0 (DE-625)19237: |2 rvk | ||
| 084 | |a 610 |2 sdnb | ||
| 245 | 1 | 0 | |a Neuroprotection |b models, mechanisms and therapies |c ed. by Mathias Bähr |
| 264 | 1 | |a Weinheim |b Wiley-VCH |c 2004 | |
| 300 | |a XX, 369 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Neurobiologie moléculaire | |
| 650 | 4 | |a Système nerveux - Maladies - Traitement | |
| 650 | 4 | |a Disease Models, Animal | |
| 650 | 4 | |a Molecular Biology | |
| 650 | 4 | |a Molecular neurobiology | |
| 650 | 4 | |a Nervous System Diseases |x therapy | |
| 650 | 4 | |a Nervous system |x Diseases |x Treatment | |
| 650 | 4 | |a Neurodegenerative Diseases |x therapy | |
| 650 | 4 | |a Neuroprotective Agents |x pharmacology | |
| 650 | 0 | 7 | |a Neuroprotektivum |0 (DE-588)4675103-8 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Neuroprotektivum |0 (DE-588)4675103-8 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Bähr, Mathias |e Sonstige |0 (DE-588)11114440X |4 oth | |
| 856 | 4 | 2 | |m SWB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010634962&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-010634962 | ||
Record in the Search Index
| _version_ | 1804130422376890368 |
|---|---|
| adam_text | CONTENTS PREFACE V LIST OF CONTRIBUTORS XVII I NEUROLOGICAL DISORDERS -
EPIDEMIOLOGY, CLINICAL OVERVIEW, AND MODEL SYSTEMS 1 STROKE 1 ANDREAS
MDSD, KONSTANTIN PRASS, TILO WOLF, ULRICH DIRNAGL ABSTRACT 1 1.1
INTRODUCTION 1 1.2 THE PENUMBRA CONCEPT 4 1.3 EXCITOTOXICITY 5 1.4
OXYGEN FREE RADICALS 5 1.5 TISSUE ACIDOSIS 6 1.6 PERI-INFARCT
DEPOLARIZATIONS 7 1.7 INFLAMMATION 8 1.8 DAMAGE TO THE
BLOOD-BRAIN-BARRIER 10 1.9 PROGRAMMED CELL DEATH AND APOPTOSIS 11 1.10
ISCHEMIA-INDUCED DNA DAMAGE, DNA REPAIR, AND P53 AS GENOTOXIC SENSOR 13
1.11 EPIGENETICS 25 1.12 GENE EXPRESSION 16 1.13 CELL REPLACEMENT 17
1.14 ENDOGENOUS NEUROPROTECTION - ISCHEMIC TOLERANCE 19 1.15 STROKE
INDUCED IMMUNE DEPRESSION (SIDS) 20 1.16 CONCLUSION 21 REFERENCES 22 2
PARKINSON S DISEASE 29 MARINA ROMERO-RAMOS, MATTHEW MAINGAY AND DENIZ
KIRIK 2.1 EPIDEMIOLOGY OF PARKINSON S DISEASE 30 2.1.1 GENETIC
CONTRIBUTION 30 NEUROPROTECTION. MODELS, MECHANISMS AND THERAPIES.
EDITED BY MATHIAS BAHR COPYRIGHT 2004 WILEY-VCH VERLAG GMBH & CO.
KGAA, WEINHEIM ISBN 3-527-30816-4 CONTENTS 2.1.2 ENVIRONMENTAL FACTORS
31 2.2 OXIDATIVE STRESS IN PARKINSON S DISEASE 32 2.3 ROLE OF
ALPHA-SYNUCLEIN IN PARKINSON S DISEASE 33 2.3.1 ALPHA-SYNUCLEIN IN LEWY
BODIES 33 2.3.2 ALPHA-SYNUCLEIN AND OXIDATIVE STRESS 34 2.4 THE
INVOLVEMENT OF PROTEOSOME IN PD 36 2.4.1 PARKIN INVOLVEMENT IN PD 37 2.5
OTHER GENES INVOLVED IN FAMILIAL PARKINSON S DISEASE 39 2.6 NEUROTOXIC
PD MODELS 39 2.6.1 OXIDATIVE STRESS 40 2.6.2 DOPAMINE
HOMEOSTASIS/COMPLEX I 40 2.6.3 PROTEASOME 41 2.7 GENETIC MODELS OF
PARKINSON S DISEASE 41 2.7.1 ALPHA-SYNUCLEIN OVEREXPRESSING TRANSGENK
ANIMALS 41 2.7.2 PARKIN-RELATED GENETIC MODELS 42 2.7.3 VIRAL VECTORS
FOR IN VIVO GENE TRANSFER OF DISEASE-RELATED PROTEINS TO THE CNS 43
2.7.3.1 LOCAL OVER EXPRESSION OF ALPHA-SYNUDEIN 43 2.7.3.2 LOCAL
OVEREXPRESSION OF PARKIN-RELATED PROTEINS 45 ACKNOWLEDGEMENTS 45
REFERENCES 45 3 AMYOTROPHIC LATERAL SCLEROSIS 49 GEORG HAASE 3.1 HUMAN
MOTOR NEURON DISEASES 49 3.1.1 FAMILIAL ALS LINKED TO SOD1 MUTATIONS 50
3.1.2 JUVENILE ALS LINKED TO ALSIN MUTATIONS 51 3.2 CELL CULTURE MODELS
OF MOTONEURON DEGENERATION 51 3.2.1 NEURONAL CELL LINES 51 3.2.2
ISOLATED MOTONEURON CULTURES 52 3.2.3 ORGANOTYPIC CULTURES 53 3.3 ANIMAL
MODELS OF MOTOR NEURON DISEASE 53 3.3.1 AXOTOMY MODELS 54 3.2 MUTANT
SOD1 MICE 54 3.3.3 PMN MICE 59 3.4 FUTURE NEUROPROTECTIVE APPROACHES 60
3.4.1 AXONAL PROTECTION 60 3.4.2 MUTANT SOD1 KNOCKDOWN BY RNA
INTERFERENCE 61 3.5 CONCLUSION 61 REFERENCES 6 1 4 ALZHEIMER S DISEASE
AND OTHER NEURODEGENERATIVE DISEASES 69 PHILIPP ]. KAHLC AND CHRISTIAN
HAASS ABSTRACT 69 4.1 INTRODUCTION 70 CONTENTS 4.2. TRANSGEMC
INVERTEBRATES 70 4.3 TRANSGENIC MICE 7 1 4.3.1 TYROSINE HYDROXYLASE (TH)
PROMOTER 71 4.3.2 PLATELET-DERIVED GROWTH FACTOR-/? (PDGF/I) PROMOTER 72
4.3.3 THYL PROMOTER 72 A3 A PRIORI PROTEIN (PRP) PROMOTER 73 4.3.5 GLIAI
EXPRESSION 74 4.4 VIRAL MODELS 75 4.5 CONCLUSION AND OUTLOOK 76
REFERENCES 76 5 CNS INFLAMMATION 83 CHRISTINE STADELMANN AND WOLFGANG
BRIICK 5.1 INTRODUCTION 8.3 5.2 THE PATHOLOGIC CHARACTERISTICS OF THE MS
PLAQUE 84 5.3 AXONAL PATHOLOGY IN MS 85 5.4 NEURONAL PATHOLOGY IN
MULTIPLE SCLEROSIS 86 5.5 LESSONS FROM ANIMAL MODELS 87 REFERENCES 88 6
NEUROTRAUMA 93 IBOLJA CERNAK, PAUL M, LEA IV, ALAN I. FADEN 6.1
INTRODUCTION 93 6.2 IN VIVO MODELS 94 6.2.1 STATIC BRAIN INJURY MODELS
95 6.2.2 DYNAMIC BRAIN INJURY MODELS 95 6.2.2.1 INDIRECT DYNAMIC BRAIN
INJURY 95 6.2.2.2 DIRECT DYNAMIC BRAIN INJURY 96 6.2.3 COMBINED
NEUROTRAUMA MODELS 104 6.3 IN VITRO MODELS 104 6.3.1 TENSION
STRESS-INDUCED INJURY 107 6.3.1.1 STRETCH INJURY MODELS 107 6.3.2
COMPRESSION INJURY MODELS 108 6.3.2.1 WEIGHT-DROP MODEL 209 6.3.2.2
HYDROSTATIC PRESSURE MODELS 109 6.3.2.3 FLUID-PERCUSSION MODELS 109
6.3.3 SHEAR INJURY MODELS 110 6.3.3.1 ACCELERATION MODELS 110 6.3.3.2
HYDRODYNAMIC MODEL 110 6.3.3.3 PRIMARY AXOTOMY/TRANSECTION MODELS 111
6.4 CONCLUSION 112 REFERENCES 113 XII CONTENTS 7 SPINAL CORD INJURY 127
POONAM VERRNA AND JAMES W. FAWCETT 7.1 ACUTE NEUROPROTECTION (PREVENTING
NEURONAL DEATH) 129 7.2 REGENERATION OF NERVE FIBER TRACTS (INITIATING
GROWTH FOLLOWING INJURY) 130 7.2.1 EXTRINSIC MECHANISMS 230 7.2.1.1 THE
GLIAL SCAR 131 7.2.1.2 BLOCKAGE OF GLIAL SCAR FORMATION 131 7.2.1.3
MODIFICATION OF GROWTH-INHIBITORY MOLECULES 132 7.2.1.4 SELECTIVE
REMOVAL OF ASTROCYTES 134 7.2.2 INTRINSIC NEURONAL CONTROL OF
REGENERATION 134 7.2.2.1 NEURONAL AGE 235 7.2.2.2 SITE OF TRANSECTION
135 7.2.2.3 NEURONAL VARIABILITY 236 7.3 BRIDGING CYSTS AND SCARS AND
CELLULAR REPLACEMENT 236 7.4 REPLACING LOST NEURONS 137 7.4.1 NEURAL
TRANSPLANTATION 237 7.4.2 REPLACING LOST NEURONS FROM STEM CELLS 238 7.5
TREATING DEMYELINATION 238 7.6 ENHANCING PLASTICITY 239 7.7 FUTURE
EXPECTATIONS 240 REFERENCES 242 II CELLULAR AND MOLECULAR MECHANISMS 8
APOPTOSIS AND NECROSIS 249 LAURA KORHONEN AND DAN LINDHOLM 8.1
INTRODUCTION 249 8.2 APOPTOSIS VERSUS NECROSIS 250 8.3 GENETICS OF
APOPTOSIS AND THE PROTEINS INVOLVED 252 8.3.1 CAMORHABDITIS EKGANS AS A
MODEL SYSTEM 252 8.3.2 CASPASES 253 8.3.3 ANTI-APOPTOTIC PROTEINS 255
8.4 CELLULAR MECHANISMS OF APOPTOSIS 260 8.4.1 THE ROLE OF MITOCHONDRIA
AND THE APOPTOSOME COMPLEX 260 8.4.2 CELL DEATH IN NEURODEGENERATIVE
DISEASES 162 REFERENCES 2 63 9 INFLAMMATION 269 HAROLD NEUMANN 9.1
INTRODUCTION 269 9.2 INNATE IMMUNE RESPONSES IN THE CNS 171 9.3 DUAL
MECHANISM OF INNATE IMMUNITY IN THE CNS 272 9.4 ANTIGEN PRESENTATION FOR
ADAPTIVE IMMUNE RESPONSES IN THE CNS 273 9.5 REGULATION OF ADAPTIVE
IMMUNE RESPONSES IN THE CNS 274 CONTENTS XIII 9.6 IMMUNE SURVEILLANCE OF
THE CNS BY T LYMPHOCYTES 176 9.7 EFFECTOR MECHANISMS OF LYMPHOCYTES 177
ACKNOWLEDGEMENT 1 SO REFERENCES 183 10 METABOLIC DYSFUNCTIONS 187
KONSTANTIN-A. HOSSMANN 10.1 INTRODUCTION 187 10.2 DISTURBANCES OF THE
ENERGY METABOLISM 188 10.2.1 ENERGY PRODUCTION AND TURNOVER 188 10.2.2
REDUCTION OF OXYGEN SUPPLY 188 10.3 DISTURBANCES OF FLOW-COUPLING 290
10.4 MITOCHONDRIA! DYSFUNCTION 191 10.5 IMPORTANCE OF DISTURBED ENERGY
METABOLISM FOR INJURY EVOLUTION 192 10.5.1 GLOBAL BRAIN ISCHEMIA 192
10.5.2 FOCAL BRAIN ISCHEMIA 194 10.5.3 EPILEPTIC SEIZURES 196 10.5.4
HEAD TRAUMA 197 10.6 DISTURBANCES OF PROTEIN SYNTHESIS 198 10.6.1
MECHANISMS OF DISTURBED PROTEIN SYNTHESIS 198 10.7 IMPORTANCE OF
DISTURBED PROTEIN SYNTHESIS ON INJURY EVOLUTION 200 10.7.1 GLOBAL BRAIN
ISCHEMIA 200 10.7.2 FOCAL ISCHEMIA 20.2 10.7.3 EPILEPTIC SEIZURES 203
10.7.4 HEAD TRAUMA 203 10.8 THERAPEUTICAL IMPLICATIONS 204 REFERENCES
206 11 PROTEIN MISFOLDING 209 MILENE RUSSELAKIS-CARNEIRO, CLAUDIO HETZ,
JOAQUM CASTILLA AND CLAUDIO SOTO ABSTRACT 209 11.1 INTRODUCTION 209 11.2
DISEASE PROPAGATION BY REPLICATION OF PRION PROTEIN MISFOLDING 220 11.3
PRION BIOLOGY 22 2 11.4 PRION PATHOGENESIS 214 11.5 NEURONAL TARGETING
225 11.6 NEURONAL APOPTOSIS IN PRION DISEASES 225 11.7 ER-STRESS AND
APOPTOSIS IN PRION DISEASES 226 11.8 CONCLUDING REMARKS 229 REFERENCES
220 12 AXONAL GROWTH INHIBITION 225 ANNE D. ZURN AND CHRISTINE E.
BANDTLOW 12.1 INTRODUCTION 225 12.2 INTRINSIC PROPERTIES OF CNS NEURONS
225 XIV CONTENTS 12.2.1 SURVIVAL OF INJURED NEURONS 225 12.2.2
DEVELOPMENTAL LOSS OOF REGENERATIVE ABILITY 226 12.2.3 INTRINSIC
DIFFERENCES IN GROWTH POTENTIAL 227 12.2.4 TRANSIENT EXPRESSION OF
GROWTH-ASSOCIATED MOLECULES 227 12.2.5 CONDITIONING LESION 228 12.3
EXTRINSIC FACTORS: THE CNS AS A NON-CONDUCIVE GROWTH ENVIRONMENT 229
12.3.1 CELLULAR COMPONENTS OF INHIBITION 229 12.3.1.1 THE GLIAL SCAR 229
12.3.1.2 OLIGODENDROCYTES AND MYELIN (WALLERIAN DEGENERATION) 230
12.3.1.3 SECONDARY INJURY: INFLAMMATION, CELL-MEDIATED IMMUNITY, AND
GLIAL CELL LOSS 231 12.3.1.4 GENETIC INFLUENCES ON CELLULAR REACTIONS TO
CNS INJURY 232 12.3.2 MOLECULAR COMPONENTS OF INHIBITION 232 12.3.2.1
AXON GROWTH INHIBITORS IN THE GLIAL SCAR 2.32 12.3.2.2 MYELIN-ASSOCIATED
GROWTH INHIBITORS 235 12.3.3 TRANSDUCTION OF AXON GROWTH-INHIBITORY
SIGNALS 238 12.3.3.1 RECEPTORS FOR MYELIN-ASSOCIATED INHIBITORS 238
12.3.3.2 SIGNALING PATHWAYS OF MYELIN-ASSOCIATED INHIBITORS 239 12.4
EXPERIMENTAL STRATEGIES TO OVERCOME GROWTH INHIBITION 241 12.5
CONCLUSION 243 REFERENCES 244 13 NEUROGENESIS 257 SEBASTIAN JESSBERGER
AND GERD KEMPERRNANN 13.1 INTRODUCTION 257 13.2 NEURAL STERN- AND
PRECURSOR CELLS IN THE ADULT BRAIN 259 13.2.1 NEURAL STERN CELLS IN THE
ADULT BRAIN: IN VITRO 259 13.2.2 NEURAL STERN CELLS IN THE ADULT BRAIN:
IN VIVO 260 13.3 MATURATION AND MIGRATION OF ADULT-GENERATED NEURONS IN
THE ADULT BRAIN 262 13.4 NEUROGENESIS IN THE ADULT BRAIN - AGE
DEPENDENCY, PERSISTENCE AND GENETIC DETERMINANTS 265 13.4.1 NEUROGENESIS
IN AGED ANIMALS 265 13.4.2 LONG-TERM PERSISTENCE OF ADULT-GENERATED
NEURONS IN THE SVZ AND HIPPOCAMPUS 265 13.4.3 GENETIC INFLUENCE ON ADULT
HIPPOCAMPAL NEUROGENESIS 266 13.5 REGULATION OF ADULT NEUROGENESIS 266
13.5.1 LEARNING 267 13.5.2 ENVIRONMENTAL ENRICHMENT 267 13.5.3 PHYSICAL
ACTIVITY 268 13.5.4 STRESS AND DEPRESSION 269 13.5.5 EPILEPSY 270 13.5.6
ISCHEMIA AND CORTICAL TRAUMA 271 13.6 POSSIBLE FUNCTIONAL RELEVANCE OF
NEUROGENESIS IN THE ADULT BRAIN 272 13.7 THERAPEUTIC STRATEGIES FOR
NEURAL CELL REPLACEMENT 274 CONTENTS 13.7.1 ENDOGENOUS NEUROGENESIS 274
13.7.2 TRANSPLANTATION OF STERN- OR PRECURSOR CELLS INTO THE DAMAGED
BRAIN 274 ACKNOWLEDGEMENTS 276 REFERENCES 276 14 EXCITOTOXICITY 287
STUART A, LIPTON, MD, PHD ABSTRACT 287 14.1 INTRODUCTION 288 14.2 THE
SEARCH FOR CLINICALLY-TOLERATED NMDA RECEPTOR ANTAGONISTS 289 14.3
EXCITOTOXICITY 290 14.3.1 DEFINITION AND CLINICAL RELEVANCE 290 14.3.2
LINKS BETWEEN STROKE AND VASCULAR DEMENTIA TO EXCITOTOXIC DAMAGE 291
14.3.2.1 POSSIBLE LINKS BETWEEN EXCITOTOXIC DAMAGE AND ALZHEIMER S
DISEASE 292 14.3.3 PATHOPHYSIOLOGY OF EXCITOTOXICITY; ROLE OF THE NMDA
RECEPTOR 292 14.3.3.1 THE IMPORTANCE OF OFF-RATE FROM CHANNEL BLOCK 295
14.4 MEMANTINE 296 14.4.1 BACKGROUND AND PHARMACOLOGY: UNCOMPETITIVE
OPEN-CHANNEL BLOCK 296 14.4.2 VOLTAGE DEPENDENCE, PARTIAL TRAPPING, AND
OTHER POSSIBLE EFFECTS OF MEMANTINE 299 14.4.3 NEUROPROTECTIVE EFFICACY
300 14.5 NITROMEMANTINES 302 14.6 SUMMARY 303 ACKNOWLEDGMENTS .304
APPENDIX 304 REFERENCES 305 III THERAPIES 15 SPINAL CORD TRAUMA 311 V.
DIETZ ABSTRACT 3 11 15.1 EPIDEMIOLOGY 312 15.2 CLINICAL ASPECTS 312
15.2.1 ACUTE STAGE 312 15.2.2 DYSFUNCTION OF THE AUTONOMIC NERVOUS
SYSTEM 313 15.2.3 THE EVOLUTION OF SIGNS AND SYMPTOMS 314 15.3
PRINCIPLES OF THERAPY 315 15.3.1 GENERAL CONCEPTS 315 15.3.2 TRANSITION
FROM ACUTE CARE TO REHABILITATION 316 15.3.3 BASIC ASPECTS OF MOTOR
REHABILITATION: NEURONAL ACTIVITY OF THE ISOLATED SPINAL CORD 316 15.4
CURRENT APPROACHES IN MOTOR REHABILITATION 317 15.4.1 SPINAL REFLEX
PLASTICITY 318 15.4.2 USE-DEPENDENT PLASTICITY - REHABILITATIVE
APPROACHES 318 XVI CONTENTS 15.4.3 TASK-SPECIFIC PLASTICITY 319 15.4.4
EFFECTS OF LOCOMOTOR TRAINING IN SPINAL CORD INJURY 319 15.5 SEARCH FOR
RELIABLE CLINICAL ASSESSMENT 321 15.5.1 PHYSICAL SIGNS AND FUNCTION 321
15.5.2 APPROPRIATE ASSESSMENT OF FUNCTION - BASIS FOR NEW INTERVENTIONAL
THERAPIES 322 15.6 CONCLUSION 324 REFERENCES 325 16 NEURODEGENERATION
329 JORG B. SCHULZ, MD 16.1 WHAT IS NEUROPROTECTION? .329 16.2 OUTCOME
MEASURES IN CLINICAL STUDIES 330 16.3 SPECIFIC DISEASES 331 16.3.1
WILSON S DISEASE 331 16.3.2 PARKINSON S DISEASE 332 16.3.2.1 DATATOP
STUDY 332 16.3.2.2 DOPAMINE AGONISTS 332 16.3.2.3 ANTI-EXCITOTOXIC
TREATMENT 333 16.3.2.4 NEUROTROPHINS 333 16.3.2.5 MAP KINASE INHIBITORS
334 16.3.2.6 TRANSPLANTATION 334 16.3.2.7 DEEP BRAIN STIMULATION 335
16.3.2.8 COENZYME Q 10 335 16.3.3 MULTIPLE SYSTEM ATROPHY AND
PROGRESSIVE SUPRANUCLEAR PALSY 335 16.3.4 ALZHEIMER S DISEASE 336
16.3.4.1 SYMPTOMATIC TREATMENT 336 16.3.4.2 ANTIOXIDANTS 337 16.3.4.3
ANTI-INFLAMMATORY APPROACHES 337 16.3.4.4 ESTROGEN REPLACEMENT 337
16.3.4.5 NMDA RECEPTOR ANTAGONISTS 338 16.3.4.6 EXPERIMENTAL THERAPIES
338 16.3.4.7 IMMUNIZATION 338 16.3.4.8 CHOLESTEROL-LOWERING THERAPY 340
16.3.5 HUNTINGTORIS DISEASE 341 16.4 WHY DO SO MANY CLINICAL STUDIES
FAIL? WHAT DO WE NEED? 342 REFERENCES 343 17 PERSPECTIVES FOR
NEUROPROTECTIVE THERAPIES IN BASIC RESEARCH AND CLINICAL APPLICATION 351
MATHIAS BOHR AND PAWEL KERMER REFERENCES 354 INDEX 361
|
| any_adam_object | 1 |
| author_GND | (DE-588)11114440X |
| building | Verbundindex |
| bvnumber | BV017687679 |
| callnumber-first | R - Medicine |
| callnumber-label | RC358 |
| callnumber-raw | RC358 |
| callnumber-search | RC358 |
| callnumber-sort | RC 3358 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | YG 1600 YG 4015 CZ 1380 |
| ctrlnum | (OCoLC)56538914 (DE-599)BVBBV017687679 |
| dewey-full | 616.806 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.806 |
| dewey-search | 616.806 |
| dewey-sort | 3616.806 |
| dewey-tens | 610 - Medicine and health |
| discipline | Psychologie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01832nam a2200505 c 4500</leader><controlfield tag="001">BV017687679</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20191015 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">031125s2004 gw ad|| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">969303823</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3527308164</subfield><subfield code="9">3-527-30816-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)56538914</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV017687679</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC358</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.806</subfield><subfield code="2">22</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YG 1600</subfield><subfield code="0">(DE-625)153474:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YG 4015</subfield><subfield code="0">(DE-625)153494:12921</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CZ 1380</subfield><subfield code="0">(DE-625)19237:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Neuroprotection</subfield><subfield code="b">models, mechanisms and therapies</subfield><subfield code="c">ed. by Mathias Bähr</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim</subfield><subfield code="b">Wiley-VCH</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XX, 369 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurobiologie moléculaire</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Système nerveux - Maladies - Traitement</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Disease Models, Animal</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular Biology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Molecular neurobiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nervous System Diseases</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nervous system</subfield><subfield code="x">Diseases</subfield><subfield code="x">Treatment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neurodegenerative Diseases</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neuroprotective Agents</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Neuroprotektivum</subfield><subfield code="0">(DE-588)4675103-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Neuroprotektivum</subfield><subfield code="0">(DE-588)4675103-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bähr, Mathias</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)11114440X</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">SWB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010634962&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-010634962</subfield></datafield></record></collection> |
| id | DE-604.BV017687679 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T19:20:47Z |
| institution | BVB |
| isbn | 3527308164 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-010634962 |
| oclc_num | 56538914 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XX, 369 S. Ill., graph. Darst. |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| publisher | Wiley-VCH |
| record_format | marc |
| spelling | Neuroprotection models, mechanisms and therapies ed. by Mathias Bähr Weinheim Wiley-VCH 2004 XX, 369 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Neurobiologie moléculaire Système nerveux - Maladies - Traitement Disease Models, Animal Molecular Biology Molecular neurobiology Nervous System Diseases therapy Nervous system Diseases Treatment Neurodegenerative Diseases therapy Neuroprotective Agents pharmacology Neuroprotektivum (DE-588)4675103-8 gnd rswk-swf Neuroprotektivum (DE-588)4675103-8 s DE-604 Bähr, Mathias Sonstige (DE-588)11114440X oth SWB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010634962&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Neuroprotection models, mechanisms and therapies Neurobiologie moléculaire Système nerveux - Maladies - Traitement Disease Models, Animal Molecular Biology Molecular neurobiology Nervous System Diseases therapy Nervous system Diseases Treatment Neurodegenerative Diseases therapy Neuroprotective Agents pharmacology Neuroprotektivum (DE-588)4675103-8 gnd |
| subject_GND | (DE-588)4675103-8 |
| title | Neuroprotection models, mechanisms and therapies |
| title_auth | Neuroprotection models, mechanisms and therapies |
| title_exact_search | Neuroprotection models, mechanisms and therapies |
| title_full | Neuroprotection models, mechanisms and therapies ed. by Mathias Bähr |
| title_fullStr | Neuroprotection models, mechanisms and therapies ed. by Mathias Bähr |
| title_full_unstemmed | Neuroprotection models, mechanisms and therapies ed. by Mathias Bähr |
| title_short | Neuroprotection |
| title_sort | neuroprotection models mechanisms and therapies |
| title_sub | models, mechanisms and therapies |
| topic | Neurobiologie moléculaire Système nerveux - Maladies - Traitement Disease Models, Animal Molecular Biology Molecular neurobiology Nervous System Diseases therapy Nervous system Diseases Treatment Neurodegenerative Diseases therapy Neuroprotective Agents pharmacology Neuroprotektivum (DE-588)4675103-8 gnd |
| topic_facet | Neurobiologie moléculaire Système nerveux - Maladies - Traitement Disease Models, Animal Molecular Biology Molecular neurobiology Nervous System Diseases therapy Nervous system Diseases Treatment Neurodegenerative Diseases therapy Neuroprotective Agents pharmacology Neuroprotektivum |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=010634962&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT bahrmathias neuroprotectionmodelsmechanismsandtherapies |